文献速递认知障碍与痴呆

APOE基因型与阿尔茨海默病风险在不同年龄、性别和人群祖先中的关联

APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry.
PubMed 文献 · JAMA Neurol · 2023-01-01

这项遗传关联研究纳入68 756名个体,分析APOE基因型与阿尔茨海默病(AD)风险的关联在性别、年龄、种族和民族及全球人群祖先间的分层差异。结果显示APOE*34与AD风险的比值比在东 Asian、White、Black和Hispanic个体中依次减弱;APOE*22+23在Hispanic个体中无关联,在东 Asian个体中亦无关联。研究认为这些新见解对指导AD临床试验设计和研究至关重要。

要点

  • APOE*34与AD风险的OR在东 Asian 4.54、White 3.46、Black 2.18、Hispanic 1.90。
  • APOE*22+23与AD风险的OR在White 0.53、Black 0.69、Hispanic 0.89(无关联)。
  • White个体中APOE*34的性别-by-年龄交互效应在60至70岁重现(OR 1.48)。

核心结论

  • 本研究提供了迄今最大规模的关于APOE与AD风险跨年龄、性别、种族和民族及人群祖先关联的概览。

研究设计与样本

  • 遗传关联研究,纳入病例对照、家系、人群基础和纵向AD相关队列,共68 756名独特个体。
  • 遗传数据来自高密度单核苷酸变异微阵列、外显子微阵列及全外显子组和全基因组测序。
  • 数据于2022年3月至2023年4月间分析。

主要发现

  • APOE*34与AD风险的OR在东 Asian个体为4.54(95%CI 3.99-5.17),White个体为3.46(95%CI 3.27-3.65),Black个体为2.18(95%CI 1.90-2.49),Hispanic个体为1.90(95%CI 1.65-2.18)。
  • APOE*22+23与AD风险的OR在White个体为0.53(95%CI 0.48-0.58),Black个体为0.69(95%CI 0.57-0.84),Hispanic个体为0.89(95%CI 0.72-1.10),Hispanic个体无关联。
  • APOE*22+23与AD风险在东 Asian个体无关联(OR 0.97;95%CI 0.77-1.23)。
  • Black个体中,全球非洲祖先减少或全球欧洲祖先增加显示APOE*4剂量与AD风险增加的模式,但APOE*2剂量与AD风险无此模式。
  • White个体中APOE*34的性别-by-年龄交互效应(女性风险更高)在60至70岁重现(OR 1.48;95%CI 1.10-2.01),并在Black个体和Hispanic个体的Meta分析中复制(OR 1.72;95%CI 1.01-2.94)。

局限性

  • East Asian个体的 demographic data 不可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Apolipoprotein E (APOE)*2 and APOE*4 are, respectively, the strongest protective and risk-increasing, common genetic variants for late-onset Alzheimer disease (AD), making APOE status highly relevant toward clinical trial design and AD research broadly. The associations of APOE genotypes with AD are modulated by age, sex, race and ethnicity, and ancestry, but these associations remain unclear, particularly among racial and ethnic groups understudied in the AD and genetics research fields. OBJECTIVE: To assess the stratified associations of APOE genotypes with AD risk across sex, age, race and ethnicity, and global population ancestry. DESIGN, SETTING, PARTICIPANTS: This genetic association study included case-control, family-based, population-based, and longitudinal AD-related cohorts that recruited referred and volunteer participants. Data were analyzed between March 2022 and April 2023. Genetic data were available from high-density, single-nucleotide variant microarrays, exome microarrays, and whole-exome and whole-genome sequencing. Summary statistics were ascertained from published AD genetic studies. MAIN OUTCOMES AND MEASURES: The main outcomes were risk for AD (odds ratios [ORs]) and risk of conversion to AD (hazard ratios [HRs]), with 95% CIs. Risk for AD was evaluated through case-control logistic regression analyses. Risk of conversion to AD was evaluated through Cox proportional hazards regression survival analyses. RESULTS: Among 68 756 unique individuals, analyses included 21 852 East Asian (demographic data not available), 5738 Hispanic (68.2% female; mean [SD] age, 75.4 [8.8] years), 7145 non-Hispanic Black (hereafter referred to as Black) (70.8% female; mean [SD] age, 78.4 [8.2] years), and 34 021 non-Hispanic White (hereafter referred to as White) (59.3% female; mean [SD] age, 77.0 [9.1] years) individuals. There was a general, stepwise pattern of ORs for APOE*4 genotypes and AD risk across race and ethnicity groups. Odds ratios for APOE*34 and AD risk attenuated following East Asian (OR, 4.54; 95% CI, 3.99-5.17),White (OR, 3.46; 95% CI, 3.27-3.65), Black (OR, 2.18; 95% CI, 1.90-2.49) and Hispanic (OR, 1.90; 95% CI, 1.65-2.18) individuals. Similarly, ORs for APOE*22+23 and AD risk attenuated following White (OR, 0.53, 95% CI, 0.48-0.58), Black (OR, 0.69, 95% CI, 0.57-0.84), and Hispanic (OR, 0.89; 95% CI, 0.72-1.10) individuals, with no association for Hispanic individuals. Deviating from the global pattern of ORs, APOE*22+23 was not associated with AD risk in East Asian individuals (OR, 0.97; 95% CI, 0.77-1.23). Global population ancestry could not explain why Hispanic individuals showed APOE associations with less pronounced AD risk compared with Black and White individuals. Within Black individuals, decreased global African ancestry or increased global European ancestry showed a pattern of APOE*4 dosage associated with increasing AD risk, but no such pattern was apparent for APOE*2 dosage with AD risk. The sex-by-age-specific interaction effect of APOE*34 among White individuals (higher risk in women) was reproduced but shifted to ages 60 to 70 years (OR, 1.48; 95% CI, 1.10-2.01) and was additionally replicated in a meta-analysis of Black individuals and Hispanic individuals (OR, 1.72; 95% CI, 1.01-2.94). CONCLUSION AND RELEVANCE: Through recent advances in AD-related genetic cohorts, this study provided the largest-to-date overview of the association of APOE with AD risk across age, sex, race and ethnicity, and population ancestry. These novel insights are critical to guide AD clinical trial design and research.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Belloy ME, Andrews SJ, Le Guen Y, et al. APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry. JAMA Neurol. 2023. PMID: 37930705. doi:10.1001/jamaneurol.2023.3599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。